Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods
Authors Zhang HM, Liu XY, Liu YZ, Liu LN, Lin QD, Song YP, Fang BJ
Received 11 June 2019
Accepted for publication 22 July 2019
Published 10 September 2019 Volume 2019:11 Pages 8295—8302
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 3
Editor who approved publication: Dr Sanjeev Srivastava
Hong-Mei Zhang, Xi-Yang Liu, Yu-Zhang Liu, Li-Na Liu, Quan-De Lin, Yong-Ping Song, Bai-Jun Fang
Department of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450008, People’s Republic of China
Correspondence: Bai-Jun Fang
Department of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, The Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, No. 127 Dongming Road, Zhengzhou 450008, People’s Republic of China
Tel +86 3 716 558 7318
Fax +86 3 716 558 8134
Background: This study aims to compare the efficacy and adverse reactions of bortezomib for treating newly diagnosed multiple myeloma (MM) through two different administration methods: intravenous (IV) injection and subcutaneous (SC) injection.
Methods: A retrospective analysis was performed in 205 patients with newly diagnosed MM, who were treated by the Department of Hematopathology, Henan Cancer Hospital, from June 2009 to December 2017. These patients were divided into two groups according to the treatment methods: IV injection group, IV injection of bortezomib; SC injection group, SC injection of bortezomib.
Results: After the first course of treatment, the effect of very good partial remission (VGPR) or above (≥VGPR) in the IV injection group (IV group) and SC injection group (SC group) was 31.0% and 14.3%, respectively (P=0.004), while the overall response rate (ORR) was 72.0% and 49.5%, respectively (P=0.001). From the 2nd course to the 6th course of treatment, the ORR was not statistically different between these two groups. No significant difference was found in median progression-free survival (37 vs 45 months) and overall survival (63 vs 59 months). A lower frequency of adverse events, especially Grade 3 peripheral neuropathy, was observed in SC group compared with the IV group.
Conclusion: Compared with IV administration, SC bortezomib can provide a better balance between efficacy and toxicity.
Keywords: multiple myeloma, bortezomib, intravenous injection, subcutaneous injection
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]